Seaport Therapeutics receives $100 million in funding to maximise Monash invention
April 19, 2024 | 07:20
Seaport Therapeutics, a clinical-stage biopharmaceutical company based around a unique drug delivery platform originally developed by Monash University researchers, has announced the closing of a $100 million oversubscribed Series A financing round.
Mobile Version